GLP-1 price drops to drive massive savings
The guest argued that lowering the price of GLP-1 drugs to $150-$200 will dramatically reduce chronic illness rates and return money to the American taxpayer within two years.
The argument
Obesity drives the 'four horsemen' of chronic disease: heart disease, kidney failure, liver disease, and dementia. By negotiating cash-pay prices down to $200 for injections and $150 for upcoming FDA-approved pills, the government aims to democratize access, particularly for vulnerable Medicaid and Medicare populations.
The thesis, stress-tested
✓ What validates it
- ✓Launch of FDA-approved GLP-1 pills at the discussed $150 price point
- ✓Measurable drops in Medicaid/Medicare spending on obesity-related chronic illnesses within 24 months
▸ Risks discussed
- ▸Potential supply chain and manufacturing bottlenecks as demand scales at lower price points
- ▸Long-term side effects or compliance issues with oral pill formats
Hear it yourself
"And, with the pills, it's 150. And the pills will come out, the first FDA approved pills will start this month. And so we believe at that price And so you can carefully Because zinc care pays, right. It's basically a good copy a day. At that price, we will, within two years, return money to the American taxpayer."
00:00 / 00:20
AFFILIATE LINK · ZORTIX MAY EARN A COMMISSION · NEVER A RECOMMENDATION TO TRADE